Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

Senseonics Holdings Inc (SENS) Stock Continue Upward Trend Following Results of PROMISE Study and Continued Meme Stock Craze

Related Topics

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Senseonics Holdings Inc (SENS) stock prices were up by a significant 10.77% as of the market closing on June 11th, 2021, bringing the price per share up to USD$4.01 at the end of the trading day. After-hours trading saw the stock continue to climb by 5.24%, bringing it up to USD$4.22.

SENS Gains Traction on Reddit

The recent wave of the meme stock crazy running rampant through the stock market worked in SENS’s favor. With the surge in activity regarding the stock on Reddit, the combination of high short interest and positive fundamental developments made SENS a prime target for the consort of retail investors. SENS consolidated the confidence of both existing and prospective investors with Q1 2021 reports jumping to USD$2.85 million, up from the USD$36,000 reported in the prior-year quarter.


The company’s stock price saw a surge that it has since maintained following the announcement on June 4th, 2021 by SENS of the results of their PROMISE study. The study was designed to evaluate the safety and accuracy of the next-gen Eversense CGM System for up to 180 days with reduced calibrations.

Presenting Results

The findings were presented at the University of Colorado, Denver as an oral presentation at the 14th Annual ATTD Meeting, The presentation showcased results from both the primary sensor and a secondary sensor with modified chemistry in a subset of study participants. The secondary sensor is referred to as the SBA sensor.

Scope of CGM

With the essential value of CGM for patients with diabetes, especially the demographic requiring insulin, SENS posits that it is imperative that more patients be enabled to utilize CGM. To this end, there needs to be a greater variety of choice in product features that leads to increases accessibility. With the accuracy profile demonstrated by Eversense in the PROMISE study, the role of long-term implantable CGM system is validated in its capacity to help people manage their glucose levels.

Key Results of PROMISE Study

The results reported an overall mean absolute relative difference (MARD) against reference value of 9.1% for the primary sensor, spanning 49,000 paired points. The secondary SBA sensor reported a MARD of 8.5%, spanning 12,000 paired points. The confirmed hypoglycemic alert detection rate was 93% for the primary sensor and 94% for the SBA sensor.

Future Outlook for SENS

Armed with both the promising results of the PROMISE study and the surge in value of its equity from Reddit-driven retail investors, SENS is poised to capitalize on the opportunities presented to it. The company is keen to use this momentum to establish a continued trajectory of success. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

Leave a Comment

Your email address will not be published. Required fields are marked *

Latest Posts



Download Free eBook For


100% free. stop anytime no spam